SCHEMBL988545

SCHEMBL988545

C=CONCCCC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3258913 0.93
SCHEMBL9683531 0.84
Formaldehyde SCHEMBL28242913 0.76 ADH1B (0.44)
SCHEMBL6567934 0.75
SCHEMBL28250679 0.73
SCHEMBL28325031 0.73
SCHEMBL11114293 0.71
SCHEMBL13659141 0.71
SCHEMBL29090592 0.70
SCHEMBL912854 0.69 TSHR (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116440900-A Ternary catalyst, preparation method and application 东风汽车集团股份有限公司 2023-07-18 CN claimed
CN-102516094-A Production method of butyl amide ethenol NINGXIA DONGKE PETRIFACTION CO LTD 2012-06-27 CN claimed
US-12163124-B2 Method for gene editing MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2024-12-10 US disclosed
CN-116440900-A Ternary catalyst, preparation method and application 东风汽车集团股份有限公司 2023-07-18 CN disclosed
CN-111228509-A Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles 豪夫迈·罗氏有限公司 2020-06-05 CN disclosed
CN-105899540-B Bispecific anti-hapten/anti-blood-brain barrier receptor antibodies, complexes thereof and their use as blood-brain barrier shuttles 豪夫迈·罗氏有限公司 2020-02-07 CN disclosed
EP-2823821-B1 ANTIBODY SPECIFICALLY BINDING TO DIGOXIGENIN HOFFMANN LA ROCHE (CH) 2017-02-22 EP disclosed
US-9574016-B2 Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent HOFFMANN-LA ROCHE INC. (US) 2017-02-21 US disclosed
CN-105899540-A Bispecific anti-hapten/anti-blood-brain barrier receptor antibodies, complexes thereof and their use as blood-brain barrier shuttles 豪夫迈·罗氏有限公司 2016-08-24 CN disclosed
US-20160009823-A1 COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT HOFFMANN-LA ROCHE INC. (US) 2016-01-14 US disclosed
EP-2451480-B1 A COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT HOFFMANN LA ROCHE (CH) 2015-08-19 EP disclosed
US-20120282280-A1 BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES F. HOFFMANN-LA ROCHE AG (CH) 2012-11-08 US disclosed
US-20120269723-A1 COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT F. HOFFMANN-LA ROCHE AG (CH) 2012-10-25 US disclosed
CN-102614528-A Polyconjugates for in vivo delivery of polynucleotides ARROWHEAD MADISON INC 2012-08-01 CN disclosed
CN-102516094-A Production method of butyl amide ethenol NINGXIA DONGKE PETRIFACTION CO LTD 2012-06-27 CN disclosed
EP-2451480-A1 A COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT F. Hoffmann-La Roche AG (CH) 2012-05-16 EP disclosed
EP-2451479-A1 BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES F. Hoffmann-La Roche AG (CH) 2012-05-16 EP disclosed
WO-2011003557-A1 A COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT F. HOFFMANN-LA ROCHE AG (CH) 2011-01-13 WO disclosed
WO-2011003780-A1 BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES F. HOFFMANN-LA ROCHE AG (CH) 2011-01-13 WO disclosed
CN-101500548-A Polyconjugates for in vivo delivery of polynucleotides HOFFMANN LA ROCHE (CH) 2009-08-05 CN disclosed